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Introduction
The peroxisome is an organelle that makes an essential
contribution to cellular metabolism (van den Bosch et al., 1992).
In humans, the essential nature of the peroxisome is
underscored by a group of genetic disorders involving
peroxisomal metabolic dysfunction and widespread organ
pathology (Moser, 1993; Schutgens et al., 1986). Peroxisomal
disorders have been classified into two main categories: the
peroxisome biogenesis disorders (PBDs), represented by the
severe Zellweger syndrome (ZS), in which the peroxisome lacks
most or multiple content proteins and sometimes membrane,
and single-enzyme disorders, in which there is loss of a specific
component of a peroxisomal metabolic pathway (Gould et al.,
2001; Moser, 1993; Moser, 1996; Wanders et al., 1995).
Whereas the genetic basis of most peroxisomal disorders is now
known (Gould and Valle, 2000; Wanders and Waterham, 2005;
Weller et al., 2003), the molecular pathogenesis of the multi-
system abnormalities in these disorders, including the severe
neurodegeneration, is still unresolved.
A proposed alternative means of differentiating peroxisomal
disorders that crosses the traditional clinical, genetic and
biochemical criteria is based on peroxisome abundance and
morphology (Chang et al., 1999). Disorders of low peroxisome
abundance include ZS and two single-enzyme disorders, acyl-
CoA oxidase deficiency and D-bifunctional protein (D-BP; or
multifunctional enzyme/protein 2, MFE2/MFP2) deficiency.
The ‘peroxisome abundance’ classification also seemingly
accounts for the morphological differences of peroxisomes in
the different disorders: in ZS, remnant peroxisomes are present
as ‘membrane ghosts’, enlarged vesicles lacking content
proteins (Santos et al., 1988); in both D-BP deficiency and
acyl-CoA oxidase deficiency, peroxisomes are also enlarged,
for reasons that are not understood, and comparable in size to
ZS ghosts (Hughes et al., 1990; Poll-The et al., 1988; Suzuki
et al., 1994; van Grunsven et al., 1999). By contrast,
peroxisomes are of normal abundance and morphology in other
single-enzyme or single-protein deficiencies such as X-linked
adrenoleukodystrophy (X-ALD), and in rhizomelic
In contrast to peroxisomes in normal cells, remnant
peroxisomes in cultured skin fibroblasts from a subset of
the clinically severe peroxisomal disorders that includes the
biogenesis disorder Zellweger syndrome and the single-
enzyme defect D-bifunctional protein (D-BP) deficiency,
are enlarged and significantly less abundant. We tested
whether these features could be related to the known role
of microtubules in peroxisome trafficking in mammalian
cells. We found that remnant peroxisomes in fibroblasts
from patients with PEX1-null Zellweger syndrome or D-BP
deficiency exhibited clustering and loss of alignment along
peripheral microtubules. Similar effects were observed for
both cultured embryonic fibroblasts and brain neurons
from a PEX13-null mouse with a Zellweger-syndrome-like
phenotype, and a less-pronounced effect was observed for
fibroblasts from an infantile Refsum patient who was
homozygous for a milder PEX1 mutation. By contrast, such
changes were not seen for patients with peroxisomal
disorders characterized by normal peroxisome abundance
and size. Stable overexpression of PEX11 to induce
peroxisome proliferation largely re-established the
alignment of peroxisomal structures along peripheral
microtubules in both PEX1-null and D-BP-deficient cells.
In D-BP-deficient cells, peroxisome division was apparently
driven to completion, as induced peroxisomal structures
were similar to the spherical parental structures. By
contrast, in PEX1-null cells the majority of induced
peroxisomal structures were elongated and tubular. These
structures were apparently blocked at the division step,
despite having recruited DLP1, a protein necessary for
peroxisome fission. These findings indicate that the
increased size, reduced abundance, and disturbed
cytoplasmic distribution of peroxisomal structures in
PEX1-null and D-BP-deficient cells reflect defects at
different stages in peroxisome proliferation and division,
processes that require association of these structures with,
and dispersal along, microtubules.
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chondrodysplasia punctata (RCDP), the latter representing the
non-Zellweger syndrome class of biogenesis disorders
characterized by loss of PTS2 import (Purdue et al., 1999;
Purdue et al., 1997; Smith et al., 1999). Intriguingly, Gould and
colleagues (Chang et al., 1999; Li and Gould, 2002; Schrader
et al., 1998) demonstrated that the reduced peroxisome
abundance of ZS cells could be restored by overexpression of
the peroxisomal membrane protein PEX11, a peroxin
implicated in peroxisome proliferation and division (Schrader
et al., 1998). These findings indicate that remnant peroxisomes
are competent for PEX11-mediated proliferation and
division, and that this process does not require peroxisomal
metabolic activity (Li and Gould, 2002).
In the context of these findings, the phenotype of the
PEX11-null mouse is of particular relevance. Peroxisomes,
with an apparent complement of content proteins, are present
in PEX11-null cells (Li et al., 2002b). Surprisingly, however,
these mice show the clinical hallmarks of the severe ZS
phenotype, but little loss of the ‘signature’ peroxisomal
metabolic pathways of VLCFA -oxidation and ether lipid
(plasmalogen) synthesis (Li et al., 2002b). In exploring an
alternative explanation for the molecular pathogenesis of
PEX11-null mice, it is of interest that two significant changes
accompanied the loss of cellular PEX11, namely reduced
peroxisome abundance and increased peroxisome clustering.
Taken together, these findings point to an alternative model of
pathogenesis in which disease phenotype correlates with
abnormalities in peroxisome abundance and/or distribution in
cells.
One cellular process that may provide a unifying theme for
these findings is microtubule-based peroxisome
morphogenesis and movement. Previous studies have
established that peroxisomes associate with microtubules, and
that microtubule-mediated peroxisome motility is the
primary mode of regulation of peroxisome morphology
and trafficking in cells (Rapp et al., 1996; Schrader,
2001; Schrader et al., 1996; Schrader et al., 2000;
Thiemann et al., 2000; Wiemer et al., 1997). Also, in the
context of disease pathogenesis, it is now acknowledged
that mutations affecting proteins involved in intracellular
trafficking via the cytoskeleton underlie many
neurodegenerative diseases (Aridor and Hannan, 2000).
In this research, we have tested the hypothesis that
microtubule-mediated peroxisome trafficking is
perturbed in cells with reduced abundance and altered
cytoplasmic distribution of remnant peroxisomes. We
demonstrate a striking change to the cytoplasmic
distribution of peroxisomal structures in such cells, and
show that the abundance, cytoplasmic distribution and
alignment along microtubules of these structures can be
restored by overexpression of PEX11. We interpret this
result to indicate that peroxisome proliferation, division
and trafficking along microtubules are mechanistically-
related processes that occur independently of
peroxisomal metabolic activity.
Results
Peroxisomes are distributed along microtubules in
normal human and mouse fibroblasts
It has been demonstrated that peroxisomes associate with
microtubules in certain mammalian cell types (Schrader,
2001; Schrader et al., 1996; Schrader et al., 2000; Schrader et
al., 2003; Wiemer et al., 1997), but such an association has not
been well established for mouse or human fibroblasts. To detect
peroxisomal membranes in both normal cells and those with
abnormalities in peroxisome matrix content and morphology,
we prepared a rabbit antibody to the murine peroxisomal
membrane protein PEX14. The generated antibody recognized
a protein of approximately 57 kDa molecular mass, which is
in accord with that reported for the human and CHO cell
PEX14 proteins (Fransen et al., 1998; Shimizu et al., 1999).
As expected, the identified protein behaved as an organelle
protein upon analysis of liver fractions from a wild-type
mouse, in that it was distributed in a similar way to both the
peroxisomal membrane protein PEX13 and the matrix protein
catalase (Fig. 1A, left panel). In liver fractions from PEX13-
null mice, in which peroxisomal matrix protein import is
defective, PEX14 was still present, albeit at slightly lower
levels, and shifted from the organelle pellet fraction to the post-
organellar supernatant containing unimported catalase
(Maxwell et al., 2003) (Fig. 1A, right panel). This latter result
is consistent with the presence of remnant peroxisomes
(peroxisomal ghosts) with lower density and thus reduced
capacity to be pelleted by centrifugation. To validate the use of
PEX14 as a marker in cell studies, we carried out
immunofluorescence analysis of wild-type mouse embryonic
fibroblasts (MEFs; not shown) and normal human skin
fibroblasts (HSFs; Fig. 1B) expressing EGFP protein fused to
the consensus peroxisome targeting signal type 1 (PTS1). In
both cell types, the PEX14 antibody decorated cytoplasmic
organelles that had imported EGFP, confirming the specificity
of this antibody in recognizing peroxisomal structures in both
mouse and human cells.
To determine the distribution of peroxisomes relative to the
Fig. 1. PEX14 localizes peroxisomal structures in mammalian cells.
(A) Western blot analysis of mouse liver fractions. T, total liver
homogenate; P, organelle pellet; S, Post-organellar supernatant. +/+, wild-
type mice; –/–, PEX13-null mice. (B) Immunofluorescence microscopy of a
normal human skin fibroblast transfected with plasmid expressing EGFP-













microtubule network in cultured normal control HSFs and
wild-type MEFs, we carried out fluorescence microscopy
using the PEX14 antibody in combination with an -tubulin
Journal of Cell Science 119 (4)
subunit antibody to decorate microtubules (Fig. 2A). In both
HSFs and MEFs, peroxisomes were abundant and distributed
throughout the cytoplasm. The use of confocal laser-scanning
microscopy (CLSM) to examine the proximity of
peroxisomes to peripheral microtubules revealed
that most peroxisomes aligned adjacent to and along
individual microtubules. This result concurs with
findings on other mammalian cells (Rapp et al.,
1996; Schrader, 2001; Schrader et al., 1996;
Schrader et al., 2000; Thiemann et al., 2000; Wiemer
et al., 1997).
Microtubule cytoskeleton-perturbing drugs
disrupt the spatial organization of peroxisomes
in cultured fibroblasts
To establish whether microtubules are essential for
normal peroxisome distribution in fibroblasts, we
used nocodazole, a microtubule-depolymerising drug,
to disperse the microtubule network. Treatment of
normal HSF cells with 20 M nocodazole for 20
hours led to microtubule depolymerization, as evident
by the diffuse cytoplasmic staining with tubulin
antibody (Fig. 2B, top). Peroxisomes in these cells
clustered at several locations, including at the
cytoplasmic face of the nuclear envelope. A more
extreme clustering of peroxisomes near the cell
surface was observed for normal MEFs similarly
treated (Fig. 2B, bottom). We assessed the generality
of the disruptive effect of nocodazole by also
observing effects on mitochondria, another organelle
whose motility requires microtubules (Welte, 2004).
Mitochondria in untreated cultured HSFs, stained
using MitoTracker Green FM dye, were dispersed as
an intricate reticulum throughout the cell cytoplasm
(Fig. 2C, top). In HSFs treated with nocadozole,
mitochondrial distribution was severely disrupted and
characterized by clustering near the nucleus,
including some distinct perinuclear clustering as seen
for peroxisomes (Fig. 2C, bottom). The effect was
similar in wild-type MEFs (not shown). As predicted,
these results demonstrate that perturbation of the
microtubule network leads to aberrant peroxisome
(and mitochondrial) distribution, including clustering.
The inference from these findings is that the normal
cellular distribution of peroxisomes is dependent on
motility via the microtubule network.
Fig. 2. Peroxisomes align with, and are dispersed along,
microtubules in cultured fibroblasts.
(A) Immunofluorescence microscopy of peroxisomes and
microtubules in control HSFs (top) and wild-type MEFs
(middle). Bottom panels show confocal laser-scanning
microscopy of a HSF. Green, PEX14; red, -tubulin.
(B) HSFs (top panels) and wild-type MEFs (bottom
panels) treated with 20 M nocodazole for 20 hours.
PEX14 (green); -tubulin (red). (C) Mitochondria (green)
and microtubules (red) detected using MitoTracker Green
FM dye and -tubulin antibody, respectively, in untreated
(–NCZ, top panels) and nocodazole treated (+NCZ, bottom
panels) HSFs. Bars, 20 m (top and middle panel in A;
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The distribution and microtubule association of remnant
peroxisomes is perturbed in cell lines featuring both
defective peroxisome biogenesis and reduced
peroxisome abundance
To address our primary hypothesis that reduced peroxisome
abundance and altered morphology correlate with perturbed
microtubule-based peroxisomal distribution, we carried out
immunofluorescence microscopy of HSFs from patients
representing a range of peroxisomal disorders, as well as of
MEFs from the PEX13-null mouse with a ZS-like phenotype.
In cells from a PEX1-null ZS patient (patient 4065), in
which there is loss of both PTS1 and PTS2 peroxisomal import
(Maxwell et al., 2002; Maxwell et al., 1999), the microtubule
network appeared normal, but the abundance of (remnant)
peroxisomes was reduced to ~20% of the normal level (87±14
vs 421±31 peroxisomes/cell for normal control cells; mean ±
s.e.m., n=5 cells/experiment), whereas the size of these
structures was increased (cross-sectional area of 14.0±1.1
pixels vs 9.8±1.5 pixels for normal controls; n=5) (Fig. 3A).
These latter observations are in accord with results from
previous studies and reflect the formation of fewer, enlarged
peroxisomal vesicular ‘ghosts’ (Chang et al., 1999; Santos et
al., 1988). Of particular interest, however, was the spectacular
change in the distribution of these remnant peroxisomes in
PEX1-null cells, characterized by varying degrees of clustering
and altered distribution. Cells fell into three roughly equally
represented groups (Fig. 3A): the first group (top) showed
slight retraction of peroxisomal structures towards the cell
center and minor clustering; the second group (middle) showed
more pronounced perinuclear segregation of peroxisomal
structures, again with minor clustering; the third group
(bottom) showed striking clustering of most peroxisomal
structures at different locations in different cells, but never at
the microtubule organizing centre (MTOC, see arrow).
Although we predicted that the peroxisomal structures in these
cells might no longer associate with microtubules, CSLM
showed instead that most, but not all, of these structures were
still aligned along microtubules (Fig. 3B).
As additional controls, we demonstrated that the
peroxisomal structures in PEX1-null cells did not colocalize
with LysoTracker dye (Fig. 3C), thereby discounting a
potential accumulation in lysosomes as part of an autophagic
process. We also tested for possible changes to the distribution
of mitochondria in these cells using MitoTracker dyes. The
mitochondrial network (Fig. 3D) was not significantly altered
when compared with those in normal control cells. A similar
result was shown for PEX13-null MEFs (not shown).
Moreover, there was apparent absolute fluorescence
colocalization in these cells of MitoTracker Red CM-H2XRos
dye (representative of actively respiring mitochondria) and
MitoTracker Green FM dye (a measure of mitochondrial
abundance) (Fig. 3D), a finding that is consistent with normal
metabolic activity of the majority of mitochondria in these
cells. Thus, the organelle-trafficking defect observed for
peroxisomes does not extend to mitochondria, nor, we assume,
other organelles.
Fig. 3. Peroxisome abundance and distribution along peripheral
microtubules are perturbed in PEX1-null ZS cells. (A) PEX1-null
patient HSFs processed with antibodies against PEX14 (green) and
-tubulin (red). Top panels, minimal retraction of remnant
peroxisomes; middle panels, pronounced remnant peroxisome
retraction, with initial signs of clustering; bottom panels, dramatic
clustering of remnant peroxisomes. Arrow indicates MTOC,
corresponding to microtubule nucleation/anchor region. (B) Confocal
laser-scanning microscopy showing remnant peroxisomes aligning
(white arrowhead) or not aligning (white arrows) with microtubules.
(C) PEX1-null cells stained for remnant peroxisomes using PEX14
antibody (green), and for lysosomes using LysoTracker Red DND-99
(red). (D) PEX1-null HSF cells stained for mitochondria using
MitoTracker Green FM and MitoTracker Red CM-H2XRos dyes.













In cells from an IRD patient (1772), corresponding to a
milder PEX1 mutation in which PEX1 function is attenuated
but not abolished (Maxwell et al., 2002), the abundance of
remnant peroxisomes was also reduced (102±15 vs 421±31
peroxisomes/cell, n=5), but the size of these structures was not
significantly increased (11.2±1.3 pixels vs 9.8±1.5 pixels). The
association of remnant peroxisomes with the microtubule
network was also perturbed, but at a level intermediate between
that seen in normal controls and PEX1-null cells, with some of
these structures still aligned along peripheral microtubules
(Fig. 4A). Thus, this phenotype is consistent with the less
severe PEX1 mutation being reflected in a less severe
disturbance of microtubule-mediated peroxisome dispersal.
We also tested cells from an RCDP patient with PEX7
deficiency, a mutation leading to a specific defect in PTS2-
dependent peroxisomal import – this disorder differs from ZS
where both PTS1- and PTS2-dependent import are impaired.
Both abundance (432±34 vs 421±31 peroxisomes/cell, n=5)
and size (7.8±0.4 pixels vs 9.8±1.5 pixels) of remnant
peroxisomes were normal in the PEX7-deficient cells. In
addition, the peroxisomal structures were distributed uniformly
throughout these cells, including at the microtubule plus ends
near the cell surface (Fig. 4B).
The situation with the PEX13-null MEFs was similar to
that for the PEX1-null (4065) HSFs. Remnant peroxisomes
were readily detected using the PEX14 antibody, confirming
that PEX14 is recruited to peroxisomal membranes in the
absence of PEX13. These remnant structures were mostly
located near the cell centre, displayed some minor clustering
(Fig. 5A), reduced abundance (104±21 vs 284±43
peroxisomes/cell for normal control cells; mean ± s.e.m.,
n=5) and significantly increased size (15.2±1.3 vs 8.0±0.3
pixels for normal controls; n=5). As abnormal neuronal
Journal of Cell Science 119 (4)
migration and neurodegeneration are hallmarks of severe
peroxisomal disorders, and a feature of the PEX13-null
mouse (Maxwell et al., 2003), we also tested whether the
distribution of remnant peroxisomes was perturbed in
cultured brain neurons from these mice. We found that
whereas in PEX13 heterozygous neurons peroxisomes were
abundant and distributed throughout the cell soma and along
cell processes, in PEX13-null neurons, the remnant
peroxisomes were clustered and restricted to the cell soma
(Fig. 5B), similar to the effect observed for PEX13-null
MEFs. Astrocytes in these cultures showed the same somal
concentration of remnant peroxisomes (not shown).
Thus, the loss of distribution of remnant peroxisomes along
microtubules, and specifically peripheral microtubules, only
occurs in cells with a peroxisome biogenesis defect where the
defect also leads to significantly reduced peroxisome
abundance.
Distribution and microtubule association of remnant
peroxisomes is also perturbed in single-enzyme
disorders with reduced peroxisome abundance
To determine whether perturbations in peroxisomal distribution
and microtubule association were also characteristic of cells
from patients with a single-enzyme defect in which there is
also a concomitant reduction in peroxisome abundance, we
Fig. 4. Peroxisome abundance and distribution along peripheral
microtubules are perturbed in fibroblasts from patients with IRD but
not RCDP. Abundance and distribution of remnant peroxisomes
along microtubules of cultured patient HSFs from patients with IRD
(A) and RCDP (B), assessed by immunofluorescence using PEX14
(green) and -tubulin (red) antibodies. Bars, 20 m.
Fig. 5. Cultured MEFs and neurons from PEX13-null mice exhibit
decreased remnant peroxisome abundance and distribution along
peripheral microtubules. (A) PEX13-null MEFs and (B) PEX13
heterozygote (top panel) and PEX13-null (bottom panel) neurons
(elongated cells in each case), assessed by immunofluorescence
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assessed HSFs from a D-BP deficient patient. The microtubule
network in D-BP deficient HSFs appeared normal. However
peroxisomes in these cells were larger (16.0±8.5 vs 9.8±1.5
pixels) and less abundant (71±27 vs 421±31) than in normal
cells and showed the perturbation of peroxisomal distribution
and microtubule alignment typical of PEX1-null Zellweger
syndrome HSFs (Fig. 6A). CLSM demonstrated that most
residual peroxisomes in these cells still aligned with
microtubules (Fig. 6B). For comparison, we also analyzed cells
from an X-ALD patient, as peroxisome abundance has
previously been shown to be normal for such patients (Chang
et al., 1999). We found that cells from this patient showed near-
normal peroxisomal abundance (272±24 vs 421±31
peroxisomes/cell), normal peroxisome size (11.8±1.1 vs
9.8±1.5 pixels) and, of particular relevance here, normal
cytoplasmic distribution and alignment of these peroxisomes
along microtubules (Fig. 6B).
Taken together, the results indicate that a significant
reduction in peroxisome abundance (down to ~20% of the
normal level), correlates, in all cases, with loss of distribution
of remnant peroxisomes along peripheral microtubules.
Expression of PEX11 in PEX1-null and D-BP-deficient
cells induces proliferation and distribution of different
types of peroxisomal structures along peripheral
microtubules
The previously reported effect of PEX11 in increasing the
abundance of peroxisome ghosts (Chang et al., 1999; Li and
Gould, 2002; Schrader et al., 1998) implied that this effect may
have also restored the distribution of these structures along
microtubules. To test this, we generated PEX1-null and D-BP-
deficient cells stably overexpressing a C-terminal myc-epitope-
tagged version of human PEX11 (PEX11myc). We
observed that PEX11myc overexpression led to increased
abundance of peroxisomal structures in PEX1-null (>fivefold)
and D-BP deficient (>threefold) cells, and to a more uniform
cellular distribution of these structures in both cases (PEX1-
null cells: Fig. 7A; D-BP deficient cells: Fig. 7D). We did not
see such effects in cells stably transfected with vector alone
(not shown). Importantly, CLSM confirmed that PEX11myc-
decorated peroxisomal structures were aligned along
peripheral microtubules in PEX1-null cells (Fig. 7C) and D-
BP deficient cells (Fig. 7F). However, the morphology of the
induced peroxisomal structures was different in the two cell
types. In D-BP-deficient cells they were spherical in shape,
similar to those in mock-transfected and untransfected D-BP
deficient cells (Fig. 7E). By contrast, many of the
PEX11myc-decorated structures in PEX1-null cells had an
elongated, tubular morphology (Fig. 7B) and exhibited
alternating bands of PEX11myc immunostaining, similar to
those previously identified following the very early periods of
PEX11 activity (Schrader et al., 1998). We interpret these
findings to indicate that in response to PEX11
overexpression, peroxisomes in D-BP deficient cells are
competent for proliferation and division to daughter organelles,
whereas remnant peroxisomes in PEX1-null cells are
competent for proliferation but are blocked, at least partially,
at the division step.
DLP1 recruitment to induced peroxisomes
A recently reported function of PEX11 is to recruit the
dynamin-like protein DLP1 to the peroxisomal membrane, at
sites where PEX11 itself is sequestered away from other
peroxisomal membrane proteins. It has been suggested that the
role of DLP1 at this site may be to act as a ‘pinchase’ to release
the daughter organelle (Koch et al., 2003; Li and Gould, 2003;
Schrader et al., 1998). In view of this potentially central role
of DLP1, we tested for DLP1 association with remnant
peroxisomal membranes in D-BP deficient cells and PEX1-null
cells using CLSM. In untransfected cells, DLP1 was essentially
segregated from peroxisomal structures in both cases (Fig. 8A).
In D-BP-deficient cells overexpressing PEX11myc, DLP1
was detected on a sub-population of peroxisomal structures.
DLP1 was more abundant on the PEX11myc-decorated
tubular structures generated in PEX1-null cells (Fig. 8B). For
D-BP deficient cells, we interpret these findings to indicate that
the overall process of peroxisomal proliferation and division
has occurred effectively under the influence of PEX11myc,
but that DLP1 is still associated with some peroxisomes owing
to the ongoing PEX11myc activity. By contrast, for PEX1-
null cells, we speculate that PEX11myc-dependent
recruitment of DLP1 to elongating peroxisomal structures is
occurring, but this alone has not been sufficient to drive these
Fig. 6. The single-enzyme disorder, D-BP deficiency, is also
characterized by decreased cellular peroxisome abundance and
distribution along peripheral microtubules. (A) Peroxisome
abundance and distribution along microtubules in HSFs from a D-
BP-deficient patient. (B) Confocal laser-scanning microscopic image
of a D-BP-deficient cell showing alignment of residual peroxisomes
with microtubules. (C) Abundance and distribution of peroxisomes
along microtubules in HSFs from an X-ALD patient. PEX14, green;













peroxisomal structures through the division step, thus
explaining the significantly greater retention of DLP1 at these
membranes.
Discussion
Reduced (remnant) peroxisome abundance is a feature
common to a number of peroxisomal disorders (Chang et al.,
1999). Disorders with this phenotype do not belong to any one
genetic or disorder sub-group, but comprise those at the severe
end of the Zellweger spectrum, along with the two single-
enzyme disorders D-BP deficiency and acyl-CoA oxidase
deficiency (Chang et al., 1999). Reduced peroxisome
abundance of this order is not a feature of the remaining
peroxisomal disorders, which include the non-Zellweger
Journal of Cell Science 119 (4)
biogenesis disorder RCDP, and other single-enzyme or single-
protein disorders such as X-ALD. Our findings here concur
with these previously reported relationships, but extend this
link to include an effect on the distribution of peroxisomes
along the microtubule network. Specifically, our data indicate
that reduced abundance of remnant peroxisomes correlates
with decreased dispersion of these structures along peripheral
microtubules.
Vesicle and organelle transport along microtubules can be
both plus-end kinesin-directed and minus-end dynein-directed.
We demonstrated that most remnant peroxisomes of PEX1-null
and D-BP-deficient cells were still aligned with microtubules,
but principally with the more centrally located regions of
microtubules. Clustering of these structures was also observed
in many cells, but this was not specifically at the
MTOC – this effect therefore does not appear to
represent a shift to minus-end transport. Instead, the
general defect is more consistent with an inability
of remnant peroxisomes, once associated with
centrally located segments of microtubules, to
travel towards the cell periphery. Our additional
data indicate that microtubule morphology and
function per se are not affected in these cells, but
that the loss of microtubule-mediated plus-end
peroxisome dispersal is inherent in the molecular
properties of the abnormal peroxisomal structures.
A possible explanation for the observed
clustering of remnant peroxisomes, is that they are
sequestered for pexophagy (Farre and Subramani,
2004). However several lines of evidence do not
support this view. First, peroxisomal ghosts did not
colocalize with lysosomes, in agreement with
previous findings (Santos et al., 2000). Second,
most remnant peroxisomes still aligned with
microtubules, implying residual biological
function. Finally, PEX11 overexpression restored
the abundance and distribution of remnant
peroxisomes along peripheral microtubules,
indicating that these structures are proliferation-
and transport-competent.
The effect of PEX11myc overexpression is of
particular significance in considering a molecular
basis for these changes. The earlier findings of
Gould and co-workers demonstrated that elevated
levels of PEX11myc lead to increased peroxisome
abundance (Chang et al., 1999; Li and Gould,
2002). Our data extend these findings in
demonstrating that PEX11 restores the
distribution of newly formed peroxisomal
structures along peripheral microtubules. Thus,
microtubule-mediated distribution of the
peroxisomal structures in these cells is dependent
on the abundance of peroxisomes: overexpression
of PEX11, in inducing peroxisome proliferation,
also drives the plus-end dispersal of the newly
synthesized organelles.
The other feature common to the peroxisomal
structures of fibroblasts from ZS and D-BP-
deficient patients is their increased size. ZS cells
contain enlarged peroxisomal ghosts (Santos et al.,
2000; Santos et al., 1988), whereas the enlarged
Fig. 7. PEX11-myc overexpression leads to remnant peroxisome proliferation
and redistribution along microtubules in PEX1-null and D-BP deficient cells.
(A-C) PEX1-null and (D-F) D-BP-deficient patient HSFs stably expressing
human PEX11myc. For epifluorescence microscopy, cells were double-labeled
with PEX14 antibody (red) and myc antibody (green) (A,B,D,E). Panels B and
E are magnifications of regions shown in overlay panels in A and D,
respectively. For confocal laser-scanning microscopy, cells were double-labeled
with PEX14 antibody (green) and -tubulin antibody (red) (C and F). Bars, 20
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peroxisomes in D-BP-deficient cells presumably selectively
lack D-BP. Given the known effect of PEX11 in inducing
peroxisome proliferation, it is conceivable that these enlarged
structures represent intermediates blocked in the process of
peroxisome formation. In the main pathway of peroxisome
biogenesis, new peroxisomes form from pre-existing
peroxisomes through a pathway of elongation and division
(Gould and Valle, 2000; Lazarow and Fujiki, 1985; Purdue and
Lazarow, 2001). Although the exact function of PEX11 is
unclear, it has been shown to induce peroxisome proliferation
in normal cells – peroxisomes are converted from spherical-
shaped organelles into elongated tubules and then back into
spherical structures (Schrader et al., 1998). An essential role
for PEX11 in peroxisome formation is also indicated by the
finding that peroxisomes in hepatocytes from PEX11-null
mice are less abundant, clustered and elongated (Li et al.,
2002b; Li and Gould, 2002). It is therefore possible that
peroxisomal structures in ZS and D-BP-deficient cells have
initiated expansion (reflected in enlarged structures) but not
progressed to division. Surprisingly, however, we found
remarkably different responses of these cells to overexpression
of PEX11. In D-BP-deficient cells, induced peroxisomes had
the same spherical morphology as the parent peroxisomes,
implying that peroxisome division was driven to completion.
By contrast, in PEX1-null cells, induced peroxisomes
displayed elongated, tubular structures displaying a
PEX11myc banding pattern. These structures appear
identical to those described at early stages following
transfection of normal human skin fibroblasts with PEX11,
which were interpreted to reflect membrane sub-domains
where PEX11 segregates prior to the division step (Schrader
et al., 1998). It therefore appears that PEX11myc
overexpression in PEX1-null cells induces elongation and
tubulation of the peroxisomal ghosts, but is not sufficient to
efficiently drive the division step. Thus the peroxisomal
structures in PEX1-null cells and D-BP deficient cells are
similar in being stalled at the proliferation process, but differ
in their capacity to be driven through the division step.
What molecular changes could explain the reduced
peroxisome abundance and the different response to PEX11
overexpression? One protein implicated in the PEX11-
mediated process of peroxisome division is DLP1, a large
dynamin-like GTPase protein (Yoon et al., 1998) that tubulates
vesicle membranes in a nucleotide-dependent manner (Yoon et
al., 2001). DLP1 is necessary only for the fission step of
peroxisome division (Koch et al., 2004; Koch et al., 2003; Li
and Gould, 2003) and is recruited to the peroxisomal
membrane by PEX11 (Li and Gould, 2003). Significantly,
disruption of DLP1 function reduces peroxisome abundance
and generates organelles with long, tubular morphology (Koch
et al., 2004; Koch et al., 2003; Li and Gould, 2003). The
structures and peroxisome profile reported in these studies are
similar to those we observed in PEX1-null cells overexpressing
PEX11-myc. Thus, reduced peroxisome abundance and the
generation of tubular peroxisomes following a PEX11-
proliferative challenge are features compatible with those
resulting from abrogation of cellular DLP1 function. In
evaluating this link, we established that, as expected, DLP1
was absent from the majority of peroxisomal structures in
(untransfected) D-BP deficient cells and PEX1-null cells. In
cells overexpressing PEX11-myc, however, DLP1 was found
on membranes of some peroxisomes of D-BP-deficient cells,
and at apparent higher levels on membranes of the elongated,
tubular structures induced in PEX1-null cells. In the case of
PEX1-null cells, the retention of DLP1 on induced
peroxisomal tubules suggests that PEX11-myc has
successfully recruited DLP1 to these membranes, but that the
process of fission is blocked at a subsequent, currently
unknown step.
In these investigations, we have focused on the role of
PEX11 in peroxisome proliferation because of its established
role in peroxisome proliferation and its known involvement in
recruiting DLP1 to the peroxisomal membrane. However, the
PEX11 family also includes PEX11 and PEX11. Although
these proteins are not apparently associated with significant
changes to peroxisome abundance, PEX11 at least may have
some role in peroxisome tubulation, enlargement and
clustering (Li et al., 2002a). Therefore, future experiments
focusing on the levels of these two PEX11 proteins in patient
cells may be warranted.
As to the role of microtubules in these processes, we propose
that peroxisome proliferation and division on one hand, and
peroxisome binding to microtubules on the other hand, are
mechanistically linked processes. It is possible that peroxisome
proliferation triggers the binding and transport of newly
formed peroxisomes along microtubules. Indeed, it has been
suggested that peroxisome division would require microtubule
motor proteins to facilitate the constriction and subsequent
Fig. 8. PEX11myc overexpression recruits DLP1 to peroxisomal
structures in PEX1-null and D-BP-deficient cells. (A) Confocal laser-
scanning microscopy of untransfected PEX1-null fibroblasts, and
fibroblasts from patients deficient in D-BP double-labeled with PEX14
antibody (red) and DLP1 antibody (green). (B) Confocal laser-
scanning microscopy of PEX1-null and D-BP-deficient cells stably
expressing PEX11myc, and double labeled with c-myc antibody













division of peroxisomes (Koch et al., 2003). This is in accord
with recent findings that demonstrate a requirement for
microtubules in the earliest stages of peroxisome biogenesis
(Brocard et al., 2005).
What is the potential impact of defective microtubule-mediated
peroxisome transport? In normal cells, peroxisome transport to
cytoplasmic regions would be necessary for specific metabolic
imperatives, such as oxidation of fatty acids, synthesis of ether
lipids, or disposal of reactive oxygen species. Interestingly, one
of the common pathological consequences of ZS, D-BP
deficiency and acyl-CoA oxidase deficiency, is
neurodegeneration. In this investigation, we established that
cultured brain neurons from the PEX13-null mouse also exhibit
a reduction in abundance, and loss of distribution, of remnant
peroxisomes along peripheral microtubules. We therefore
speculate that loss of peroxisome trafficking in typical high-
energy-dependent, multi-polar brain neurons could lead to
degeneration of these cells. Equally, regional loss of peroxisomes
could lead to oxidative damage. Indeed, overexpression of tau,
which inhibits kinesin-dependent transport of peroxisomes,
increases vulnerability of neurons to oxidative stress (Stamer et
al., 2002). Regional loss of essential peroxisomal metabolism
would also appear to reconcile the ZS-like phenotype of the
PEX11-null mouse, characterized by reduced peroxisome
abundance, peroxisome clustering, and a mild defect in neuronal
migration (Li et al., 2002b). However it remains to be established
whether regional loss of peroxisomal activities are causative in
the molecular pathogenesis of these disorders.
Materials and Methods
Plasmid constructs
A pcDNA3-based plasmid encoding human PEX11 protein fused to a C-terminal
myc epitope tag (pcDNA3-PEX11) was created by PCR of human cDNA using
primers PEX11-F 5-GGTGGTGTTGGATCCGTCATGGACGCCTGGGTCC-
GCTTCAGTG-3 and PEX11-myc-R 5-GGTGTTGAATTCTCACAGGTCC-
TCCTCGGAGATCAGCTTCTGCTCGGGCTTGAGTCGTAGCCAGGGATAG-3
(myc tag codons underlined). The product was cloned into the BamHI/EcoRI sites
of pcDNA3 (Gibco-Invitrogen, Melbourne, Australia). The PTS2-EGFP plasmid,
encoding the minimal rat PTS2 signal fused to the N-terminal end of EGFP, has
been described (Maxwell et al., 2003). A pcDNA3-based plasmid expressing PTS1
fused to the C-terminus of EGFP was a gift from S. Gould (Johns Hopkins
University, Baltimore, MD). The mouse PEX14 ORF was isolated by PCR from
brain cDNA of C57BL/6J wild-type mice using the primers JB303 5-
CCCAAGCTTATGGCGTCGTCGGAGCAGGCAGAG-3 (restriction enzyme site
underlined) and JB304 5-CGCGGATCCCTAGTCTCGCTCAGTCTCATTGC-
TGG-3. This product was cloned into the HindIII/BamHI sites of pcDNA3 (Gibco-
Invitrogen) to generate pcDNA3-MmPEX14. To generate an expression plasmid
encoding a maltose-binding protein (MBP) fusion with full-length mouse PEX14
protein (MBP-MmPEX14), a PCR product obtained using pcDNA3-MmPEX14
template and primers JB305 5-CTAGTCTAGAATGGCGTCGTCGGAGCAGG-
CAGAG-3 and JB307 5-AAAACTGCAGCTAGTCTCGCTCAGTCTCATTGC-
TGG-3, was cloned into the XbaI/PstI sites of pMal-c2 (New England Biolabs,
Beverly, MA). A second expression plasmid, encoding a glutathione-S-transferase
(GST) fusion with full-length PEX14 (GST-MmPEX14), was generated by PCR
from the same template using primers JB308 5-ACGCGTCGACATGGCG-
TCGTCGGAGCAGGCAGAG-3 and JB310 5-ATAAGAATGCGGCCGCGTC-
TCGCTCAGTCTCATTGCTGG-3, and cloned into the SalI/NotI sites of pGEX5x-
3 (Amersham plc, Buckinghamshire, UK). The fusion proteins were expressed in
bacteria and purified using protocols previously described (Bjorkman et al., 2002;
Crane et al., 1994; Gould et al., 1996; Urquhart et al., 2000).
Cells and cell culture
Human skin fibroblasts (HSFs) from a PEX1-null ZS patient (4065) and an infantile
Refsum disease (IRD) patient with residual PEX1 activity (1772) have been
previously characterized (Maxwell et al., 2002). The D-BP deficient (patient IC)
(Paton and Pollard, 2000; Paton et al., 1996), X-ALD and PEX7-deficient RCDP
cell lines were from patients with typical clinical and biochemical findings for the
respective disorder. In each case, diagnosis was confirmed by molecular analysis of
the relevant gene. Mouse embryonic fibroblast (MEF) cultures were generated from
day 13 p.c. embryos. Embryos were extracted, minced and incubated in 0.25%
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trypsin in Earle’s balanced salt solution overnight at 4°C (Freshney, 1994), the tissue
triturated, and cellular debris allowed to settle under gravity. The supernatant
containing dispersed cells was removed and centrifuged at 250 g for 5 minutes and
the cell pellets resuspended in culture medium. All fibroblasts were cultured in
Dulbecco’s modified Eagle’s medium: Ham F12 supplemented with 10% fetal
bovine serum (FBS), 2 mM L-glutamine, and 100 g/ml penicillin, 100 U/ml
streptomycin (Gibco-Invitrogen). Cells were trypsinized and seeded onto coverslips
at a density to achieve approx. 60-70% confluency 16-20 hours later, then processed
for immunofluorescence. PEX1-null and D-BP deficient skin fibroblast cell lines
stably expressing PEX11 were obtained by transfection with 8 g pcDNA3-
PEX11myc (or pcDNA3, mock transfection) using the Lipofectamine 2000
transfection reagent (Gibco-Invitrogen), followed by selection using 400 M
Geneticin (Gibco-Invitrogen). The microtubule network of cells grown on glass
coverslips was dispersed by addition of 20 M nocodazole (Sigma, St Louis, MO)
to the culture medium for 20 hours prior to fixation. Mouse neuronal cell cultures
were established from whole brain tissue samples treated overnight at 4°C with 1
ml of 0.25% trypsin in cold Earle’s balanced salt solution (Gibco-Invitrogen).
Digested tissue was incubated at 37°C for 20 minutes, after which 4 ml DMEM-
F12 containing 10% fetal bovine serum, L-glutamine and penicillin/streptomycin
was added. Dissociated cells were resuspended in Neurobasal-A medium (Gibco-
Invitrogen) containing B27 supplement and 10 g/ml NGF (Gibco-Invitrogen), and
seeded onto coverslips coated with poly-L-lysine. Ethics approval for the use of
human skin fibroblasts was obtained from both the Adelaide Women’s and
Children’s Hospital Research Ethics Committee and the Griffith University Human
Ethics Committee, and for animal use from the Griffith University Animal Ethics
Committee.
Antibodies and fluorescence microscopy
PEX14 polyclonal antibodies raised against MBP-MmPEX14 fusion protein were
purified from rabbit serum by affinity chromatography using GST-MmPEX14
fusion protein covalently coupled to CNBr-activated Sepharose. Mouse monoclonal
antibodies to human -tubulin were from Sigma-Aldrich (St Louis, MO) and to
human DLP1 from BD Biosciences (Palo Alto, CA). Goat anti-mouse Alexa Fluor
488 and 568, and goat anti-rabbit Alexa Fluor 488 and 568 secondary antibodies,
were obtained from Molecular Probes (Eugene, OR). Chicken c-myc antibody and
FITC-conjugated goat anti-chicken IgG were from Santa Cruz Biotechnology
(Santa Cruz, CA). Indirect immunofluorescence was carried out as previously
described (Maxwell et al., 2003; Maxwell et al., 2002) for human skin fibroblasts
permeabilized with either 1% Triton X-100) or 25 g/ml digitonin. Epifluorescence
microscopy was carried out using a Nikon Eclipse E600 fluorescence microscope,
with image acquisition using a Photometrics Coolsnap digital camera (Roper
Scientific) and V++ Imaging software. Confocal laser-scanning microscopy was
carried out using a Leica TCS SP2 microscope (Leica Microsystems Heidelberg,
Germany). Quantification of peroxisomal abundance and size was carried out using
a MAT-lab-based algorithm (Pham et al., 2004) and expressed as the mean ± s.e.m.
of five or more separate cell analyses, from experiments replicated at least twice.
Mitochondria were visualized by fluorescence microscopy following incubation of
cultured cells for 45 minutes in medium containing 400 nM MitoTracker Red CM-
H2XRos or MitoTracker Green FM (Molecular Probes, Eugene, OR). Lysosomes
were similarly visualized following incubation of cells for 2 hours in medium
containing 100 nM LysoTracker Red DND-99 (Molecular Probes, Eugene, OR).
Identification of neurons and astrocytes in cultures was based on morphological
criteria and fluorescence microscopy using antibodies to the cell-specific markers
neurofilament 200 (Sigma) and GFAP (DAKO, Carpinteria, Denmark), respectively.
Liver fractionation and western blot analysis
Differential centrifugation of mouse liver homogenates to generate a large organelle
fraction (containing peroxisomes, mitochondria, and lysosomes) and a post-
organellar supernatant, and western blot analysis of these fractions, was carried out
as previously described (Maxwell et al., 2003).
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Laboratory for Lysosomal, Peroxisomal and Related Genetic
Disorders, Women’s and Children’s Hospital, Adelaide, for their
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the Australian Research Council (DP0208644).
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